Introduction
Tuberculosis which is caused by mycobacterium tuberculosis complex is one of the oldest disease known to affect humans and a major cause of death world wide. 1 M. tuberculosis is rod shaped non spore forming thin aerobic bacterium measuring 0.5µm by 3µm, an acid fast bacilli. It affect, lung intestine, meninges, bones, joints,lymphnodes,spleenand other tissues of the body.India is the country with the highest burden of T.B. The WHO T.B statistics for india for 2015 give an estimated incidence figure of 2.2 million cases of T.B for india out of a global incidence of 9.6 million. In Jharkhand sputum smear positive patient diagnosed in 2015 were 20544. 2 The TB prevalence is the number of people in India who are living with active TB. Prevalence is usually, but not always given as a percentage of the population. 3 Total treatment period for newly diagnosed tuberculosispatients is of 6 months including intensive and continuation phases (2 and 4 months, respectively). The intensive phase comprised of isoniazid INH (5 mg/kg day−1; maximum 300 mg/day),rifampicin RIF (10 mg/kg day−1; maximum 600 mg/day), ethambutol (EMB) (15-20 mg/kg day−1), and pyrazinamide PZA (20-25 mg/kg day−1). The continuation phase comprised daily similar doses of INH and RIF.Out of above drugs Pyrazinamide,rifampicin,isoniazid are hepatotoxic and cause increase in serum transaminase levels.
Thus present study is aimed to analyse changes in liver enzymes( ALT and AST) in different phases of treatment with antitubercular drugs. Presence of at least one of the following: i. A rise to more than 5 the upper limit of normal (ULN) level of ALT and/or AST ii. A rise in total serum bilirubin to more than 1.5 mg/dl iii. Any increase in AST and/or ALT above pre-treatment levels together with anorexia, nausea, vomiting, and jaundice.
II. Materials And Methods

Data
Baseline Evaluation:
Baseline evaluation included clinical history, physical examination, sputum smear examination, chest radiograph, abdominal ultrasonography, complete blood cell count,ESR, LFT, and hepatitis markers.
Follow-up:
Patients were followed closely fortnightly over the first 2 months, then monthly till the end of the 6-month period. In each visit, patients were assessed clinically (response to therapy, any adverse effects, and nutritional status), and biochemically including LFTs, which were repeated whenever symptoms or signs suggestive of hepatotoxicity (nausea, anorexia, malaise, vomiting, hepatomegaly, or jaundice) occurred.
III. Results
Total 55 patients were included in this study of which 2 patients developed ATT induced hepatitis and 3 patients remained sputum smear positive even after completion of intensive phase and hence were excluded from the study. 
IV. Discussion And Conclusion:
Baseline enzyme levels before therapy was within normal limits. Mean ALT level was 19.28±4.7IU/ltr while Mean AST level was20.20±5.6 IU/ltr.After 1 month of treatment most of the patients showed increase in liver enzymes, but were mostly asymptomatic with <3 fold elevation of serum transaminases.Mean ALT level at 2month was 64.10±31.8 IU/ltr while Mean AST level 48.42±12.0 IU/ltr.Thus at the end of intensive phase of treatment serum transaminase levels were in increasing trend. Mean ALT level at 3 month was 51.32±14.9IU/ltr while Mean AST level 40.60±8.8U/ltr.There was a decrease in transaminase level in continuation phase of treatment. This shows the additive effect of multidrug therapy.
Mean ALT level at the completion of continuation phase i.e at 6 month was 37.60±7.8IU/ltr while Mean AST level 32.46±5.9IU/ltr. These values were further decreased from the earlier readings taken at intensive phase and reading after commencement of continuation phase. This result is consistent with previous studies done by K.C Chang, C.C Lang & C.M Tan. 6 
